Mainstream

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model

Post ContentrprxRead More

You might also be interested in reading NGS raises 2025 adjusted EBITDA outlook to $76M–$80M while expanding capital returns and market share.

August 6, 2025
In Mainstream